Moderate-To-Severe Atopic Dermatitis
HCMHUTCHMED (China) LimitedCatalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for IMG-007 (OX40 Antagonist) in Moderate-To-Severe Atopic Dermatitis. The expected timing is based on the latest available company guidance and may change.
07/30/26:- IMG-007 Ph2b atopic dermatitis topline data are anticipated in Q4 2027.
Verification
Confirm timing and program details against the company announcement or filing.